Publications by authors named "Michael D Hogarty"

Claim this Profile
H
High-dose DFMO alters protein translation in neuroblastoma.
Andrea T Franson, Kangning Liu, Rohan Vemu, Elizabeth Scadden, Yimei Li, Michael D Hogarty

Neoplasia· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reprogramming neuroblastoma by diet-enhanced polyamine depletion.
Sarah Cherkaoui, Christina S Turn, Yuan Yuan, Wenyun Lu, Lifeng Yang, Michael D Hogarty

Nature· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sequential Combination of Unfavorable Histology followed by Clinical Stage M Defines High-Risk Neuroblastoma: A Report from the Children's Oncology Group.
Florette K Hazard, Angus M S Toland, Serena Y Tan, Bill Chiu, Naohiko Ikegaki, Michael D Hogarty

Clin Cancer Res· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Longitudinal single-cell multiomic atlas of high-risk neuroblastoma reveals chemotherapy-induced tumor microenvironment rewiring.
Wenbao Yu, Rumeysa Biyik-Sit, Yasin Uzun, Chia-Hui Chen, Anusha Thadi, Michael D Hogarty

Nat Genet· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of Image-Defined Risk Factor (IDRF) Assessment in Patients With Intermediate-risk Neuroblastoma: A Report From the Children's Oncology Group Study ANBL0531.
Erin G Brown, E Stanton Adkins, Peter Mattei, Fredric A Hoffer, Sandra L Wootton-Gorges, Michael D Hogarty

J Pediatr Surg· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes of patients with intermediate-risk neuroblastoma presenting with motor deficits relating to intraspinal tumor extension: A report from the Children's Oncology Group study ANBL0531.
Julie Voeller, Howard M Katzenstein, Arlene Naranjo, Sheena C Tenney, Lulu Chen, Michael D Hogarty

Pediatr Blood Cancer· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improvements in Children's Oncology Group neuroblastoma risk stratification through a change in age cut-off and use of INRGSS.
Wendy B London, Hannah Bousquet, Meredith S Irwin, Michael D Hogarty, Susan L Cohn

Transl Pediatr· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clofarabine monotherapy in aggressive, relapsed and refractory Langerhans cell histiocytosis.
Deevyashali Parekh, Howard Lin, Akanksha Batajoo, Erin Peckham-Gregory, Vivekanudeep Karri, Michael D Hogarty

Br J Haematol· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 study of high-dose DFMO, celecoxib, cyclophosphamide and topotecan for patients with relapsed neuroblastoma: a New Approaches to Neuroblastoma Therapy trial.
Michael D Hogarty, David S Ziegler, Andrea Franson, Yueh-Yun Chi, Denice Tsao-Wei

Br J Cancer· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reprogramming neuroblastoma by diet-enhanced polyamine depletion.
Sarah Cherkaoui, Lifeng Yang, Matthew McBride, Christina S Turn, Wenyun Lu, Michael D Hogarty

bioRxiv· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mitoribosomal synthetic lethality overcomes multidrug resistance in MYC-driven neuroblastoma.
Karolina Borankova, Maria Krchniakova, Lionel Y W Leck, Adela Kubistova, Jakub Neradil, Michael D Hogarty

Cell Death Dis· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Survival of Patients With Neuroblastoma After Assignment to Reduced Therapy Because of the 12- to 18-Month Change in Age Cutoff in Children's Oncology Group Risk Stratification.
Hannah G Bender, Meredith S Irwin, Michael D Hogarty, Robert Castleberry, John M Maris

J Clin Oncol· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Genomic and Clinical Factors on Outcome of Children ≥18 Months of Age with Stage 3 Neuroblastoma with Unfavorable Histology and without MYCN Amplification: A Children's Oncology Group (COG) Report.
Navin Pinto, Arlene Naranjo, Xiangming Ding, Fan F Zhang, Emily Hibbitts, Michael D Hogarty

Clin Cancer Res· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reduced ER-mitochondria connectivity promotes neuroblastoma multidrug resistance.
Jorida Çoku, David M Booth, Jan Skoda, Madison C Pedrotty, Jennifer Vogel, Michael D Hogarty

EMBO J· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Epigenetic state determines inflammatory sensing in neuroblastoma.
Adam J Wolpaw, Liron D Grossmann, Jessica L Dessau, May M Dong, Bailey J Aaron, Michael D Hogarty

Proc Natl Acad Sci U S A· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Histiocytic Neoplasms, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.
Ronald S Go, Eric Jacobsen, Robert Baiocchi, Ilia Buhtoiarov, Erin B Butler, Michael D Hogarty

J Natl Compr Canc Netw· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Revised Neuroblastoma Risk Classification System: A Report From the Children's Oncology Group.
Meredith S Irwin, Arlene Naranjo, Fan F Zhang, Susan L Cohn, Wendy B London, Michael D Hogarty

J Clin Oncol· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Stage 4S Neuroblastoma: Molecular, Histologic, and Immunohistochemical Characteristics and Presence of 2 Distinct Patterns of MYCN Protein Overexpression-A Report From the Children's Oncology Group.
Asuka Kawano, Florette K Hazard, Bill Chiu, Arlene Naranjo, Brian LaBarre, Michael D Hogarty

Am J Surg Pathol· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MYCN-induced nucleolar stress drives an early senescence-like transcriptional program in hTERT-immortalized RPE cells.
Sofia Zanotti, Suzanne Vanhauwaert, Christophe Van Neste, Volodimir Olexiouk, Jolien Van Laere, Michael D Hogarty

Sci Rep· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BRAF fusions in pediatric histiocytic neoplasms define distinct therapeutic responsiveness to RAF paradox breakers.
Payal Jain, Lea F Surrey, Joshua Straka, Pierre Russo, Richard Womer, Michael D Hogarty

Pediatr Blood Cancer· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Myeloablative Busulfan/Melphalan Consolidation following Induction Chemotherapy for Patients with Newly Diagnosed High-Risk Neuroblastoma: Children's Oncology Group Trial ANBL12P1.
M Meaghan Granger, Arlene Naranjo, Rochelle Bagatell, Steven G DuBois, Jeannine S McCune, Michael D Hogarty

Transplant Cell Ther· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A G316A Polymorphism in the Ornithine Decarboxylase Gene Promoter Modulates MYCN-Driven Childhood Neuroblastoma.
Laura D Gamble, Stefania Purgato, Michelle J Henderson, Simone Di Giacomo, Amanda J Russell, Michael D Hogarty

Cancers (Basel)· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical assessment of the efficacy and specificity of GD2-B7H3 SynNotch CAR-T in metastatic neuroblastoma.
Babak Moghimi, Sakunthala Muthugounder, Samy Jambon, Rachelle Tibbetts, Long Hung, Michael D Hogarty

Nat Commun· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Age Dependency of the Prognostic Impact of Tumor Genomics in Localized Resectable -Nonamplified Neuroblastomas. Report From the SIOPEN Biology Group on the LNESG Trials and a COG Validation Group.
Inge M Ambros, Gian-Paolo Tonini, Ulrike Pötschger, Nicole Gross, Véronique Mosseri, Michael D Hogarty

J Clin Oncol· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pan-neuroblastoma analysis reveals age- and signature-associated driver alterations.
Samuel W Brady, Yanling Liu, Xiaotu Ma, Alexander M Gout, Kohei Hagiwara, Michael D Hogarty

Nat Commun· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis